These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27038372)

  • 1. P2X7 Receptor as a Therapeutic Target.
    De Marchi E; Orioli E; Dal Ben D; Adinolfi E
    Adv Protein Chem Struct Biol; 2016; 104():39-79. PubMed ID: 27038372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases.
    Mishra A; Behura A; Kumar A; Naik L; Swain A; Das M; Sarangi SS; Dokania P; Dirisala VR; Bhutia SK; Mishra A; Singh R; Dhiman R
    Eur J Pharmacol; 2021 Sep; 906():174235. PubMed ID: 34097884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The P2X7 receptor: A main player in inflammation.
    Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
    Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
    Baudelet D; Lipka E; Millet R; Ghinet A
    Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.
    Al-Aqtash R; Collier DM
    Channels (Austin); 2024 Dec; 18(1):2355150. PubMed ID: 38762911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
    Bartlett R; Stokes L; Sluyter R
    Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
    Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
    Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advance in the research on P2X7 and inflammatory respiratory diseases].
    Cao SH; Yuan SP; Hou Q
    Yao Xue Xue Bao; 2013 Aug; 48(8):1183-8. PubMed ID: 24187823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2X7 receptor antagonists: a patent review (2010-2015).
    Park JH; Kim YC
    Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2X7 Receptor in Infection and Inflammation.
    Di Virgilio F; Dal Ben D; Sarti AC; Giuliani AL; Falzoni S
    Immunity; 2017 Jul; 47(1):15-31. PubMed ID: 28723547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of P2X7 receptors in tissue fibrosis: a brief review.
    Gentile D; Natale M; Lazzerini PE; Capecchi PL; Laghi-Pasini F
    Purinergic Signal; 2015 Dec; 11(4):435-40. PubMed ID: 26318434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
    Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
    Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of P2X7 receptor on inflammatory diseases and its mechanism].
    Xu H; Liang SD
    Sheng Li Xue Bao; 2013 Apr; 65(2):244-52. PubMed ID: 23598883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2X7 receptors at adult neural progenitor cells of the mouse subventricular zone.
    Messemer N; Kunert C; Grohmann M; Sobottka H; Nieber K; Zimmermann H; Franke H; Nörenberg W; Straub I; Schaefer M; Riedel T; Illes P; Rubini P
    Neuropharmacology; 2013 Oct; 73():122-37. PubMed ID: 23727220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
    El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
    Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2X7 receptor antagonism in the treatment of cancers.
    Roger S; Pelegrin P
    Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives.
    Roger S; Jelassi B; Couillin I; Pelegrin P; Besson P; Jiang LH
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2584-602. PubMed ID: 25450340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells.
    Di Virgilio F; Jiang LH; Roger S; Falzoni S; Sarti AC; Vultaggio-Poma V; Chiozzi P; Adinolfi E
    Methods Enzymol; 2019; 629():115-150. PubMed ID: 31727237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonists, Antagonists, and Modulators of P2X7 Receptors.
    Müller CE; Namasivayam V
    Methods Mol Biol; 2022; 2510():31-52. PubMed ID: 35776318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.